ABSTRACT: Synthesis of 50 analogues of the natural insecticide synergists, dillapiol and sesamol, is reported. These were evaluated as potential insecticide synergists based on their inhibition of human CYP3A4. The most potent inhibitors have a relatively large hydrophobic substituent at either position 5 or 6 of these molecules. 
■ INTRODUCTION
In our study of Mesoamerican and African traditional medicines, 1, 2 we have observed the use of plants including the genus Piper as nontargeted adjuvant agents combined with other targeted plant therapies. Extracts of these plants were found to be a potent inhibitor of enzymes of metabolism including CYP3A4, 3A5, and 3A7, which suggests that they could inhibit the metabolism at phase I of conventional drugs in vivo as well as act as pharmacoenhancers in herbal mixtures. An active inhibitory principle of the neotropical Piper aduncum was identified as the neolignan dillapiol. Dillapiol is a potent inhibitor of cytochrome CYP3A4. 3 Pharmacoenhancement by dillapiol was demonstrated in mice acutely infected with Piper berghei, where we found that dillapiol has no antimalarial activity but greatly enhanced the plasma levels and efficacy of the antimalarial compound gedunin. 4 The synergistic potential of dillapiol combined with pyrethroids against mosquitoes had also been described. 5 Dillapiol has also been long known as an insecticide synergist. A recent study reported that dillapiol effectively synergized the efficacy of pyrethrin in resistant strains of Colorado potato beetle. 6 A pilot study of a small set of dillapiol analogues with the botanical larvicide, α-terthienyl, showed that modification of the molecule could lead to more effective synergists, but the quantitative structure−activity relationship (QSAR) models were not very robust because of uncertainties in the LC 50 (lethal concentration) values. 7 Piperonyl butoxide (PBO) has been used as an insecticide synergist for more than 60 years and is today by far the most commonly used insecticide synergist. Typical databases indicate that it is a component in more than 1500 products where the active ingredient is either a synthetic or naturally occurring insecticide. 8 The ratio of PBO to active ingredient is variable depending on the application. It can range from 3:1 to 20:1 with the typical ratio being 5:1. Although PBO is generally viewed as nontoxic to humans and assigned to category IV by the US EPA, recent reports focusing on neurological developments indicate that potential problems have generated some concerns. 8−10 The European Union has recognized the need for improved insecticide synergists and announced in 2013 an award of 1 million Euros to a consortium of companies and research organizations to "develop insecticide synergists for agricultural, household, and public health use based on the knowledge of the interaction of PBO with metabolic enzymes in the insect pests".
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To gain further insight into dillapiol and its analogues as insecticide synergists, an expanded series of dillapiol analogues have been prepared for the present study by exploring a range of modifications of the parent molecule. Sesamol was also used as a starting material for the preparation of related derivatives missing one of the two methoxy groups present in dillapiol and its analogues. All analogues were evaluated in a CYP3A4 inhibition assay using a highly uniform and purified cloned commercial enzyme preparation. The inhibitory concentrations for 50% activity (IC 50 values) obtained from this method had tight confidence intervals (CIs). As the human CYP3A4 enzyme has considerable similarity with the insect versions, 12 the results from these studies should be translatable to the application of these compounds as potential insecticide synergists. Indeed, we have shown this to be the case. 13 A number of ethers derived from sesamol which are significantly more potent CYP3A4 inhibitors than dillapiol have been evaluated as potential insecticide synergists of different insecticides by BASF scientists in various locations throughout the world. The results were sufficiently promising and have prompted a European patent application. 14 
■ MATERIALS AND METHODS
CYP3A4 Inhibition Assay. Enzyme inhibition assays were conducted with cytochrome P450-BD Gentest CYP3A4 (City, State) with the CytoFluor 4000 fluorescence measurement system (Applied Biosystems, Foster City, CA) as described by Budzinski et al. 7 Briefly, assays were performed in clearbottom, opaque-welled, 96-well microtiter plates (Corning Costar, Corning, NY) using dibenzyl fluorescein (DBF, SigmaAldrich, Milwaukee, WI) as a substrate. Wells were designated as either "control", "control blank", "test", or "test blank". Control wells consist of ddH 2 O and β-nicotinamide adenine dinucleotide phosphate (NADPH) solution; control blank wells consist of H 2 O and buffer solution; test wells consist of the dillapiol analogues at a particular concentration and NADPH solution; and test blank wells consist of the corresponding analogue compounds and buffer solution. Enzyme solution was added to all wells. Fluorescence was measured at 485 nm excitation with a 20 nm bandwidth filter. All measurements were carried out in triplicate.
Statistical Analysis. Percent inhibition values were calculated based on differences in fluorescence between the control/control blank wells and test/test blank wells by the formula
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where t = X and t = 0 are the reading values of the control/ control blank/test/test blank wells at the end and beginning of running X min, respectively.
The median inhibition percent (IC 50 ) of each analogue was determined with logarithmic curves plotted by different concentration and percent inhibition. The dillapiol relative inhibition activity was obtained by the formula IC of dillapiol/IC of tested compound 50 50 As the aim of the research was to find the analogues possessing significantly higher CYP3A4 inhibition activity than dillapiol (positive control), the analogues which showed more than two times the IC 50 value higher than dillapiol were labeled as "/" and no data are shown for such compounds in Tables 1  and 2 . Statistical analysis of CIs and range of IC 50 values observed were carried out using GraphPad Prism 5; these are shown in the table of the Supporting Information.
Synthesis of Dillapiol and Sesamol Analogues. Dillapiol was obtained via steam distillation of the fruit of P. aduncum collected in the Sarapiqui region of Costa Rica. A typical distillation of 3 kg of fruit when steam distilled with 3 L of water yielded between 30 and 35 g (1 to 1.2%) of essential oil whose proton NMR indicated dillapiol with more than 95% purity. This material was considered sufficiently pure for transformation to the various intermediates and final products. Dillapiol can also be isolated by steam distillation of the leaves and branches of P. aduncum; the typical yields were in the 0.3 and 0.15% range for leaves and branches, respectively. The 15 Sesamol was purchased from Sigma-Aldrich and used as such. Standard, well-known chemical transformations were employed to produce various analogues.
A group of 17 esters was prepared via Scheme 1. Hydroboration of dillapiol, 1, with borane-dimethyl sulfide in tetrahydrofuran gave, after reductive workup, mainly the expected primary alcohol 2 along with minor amounts of the secondary alcohol 3. These isomers were separated via flash silica gel chromatography. Both isomers were esterified with different-sized aliphatic and aromatic acids either by reaction with the respective acid chloride or by coupling the acid and alcohol with the help of the coupling reagent DCC. An additional 10 esters and 14 ethers were prepared starting with sesamol in order to investigate the importance of the 4-methoxy group in dillapiol. Sesamol, 6, was O-allylated by the reaction with allyl bromide in the presence of potassium carbonate. The resultant allyl ether underwent a clean Claisen rearrangement upon heating to 190°C in decalin to give the ortho-allylated phenol 7. Subsequent O-alkylation provided ethers 8. Hydroboration of 8b (R = CH 3 ) and 8d (R = CH 2 Ph) yielded the primary and secondary alcohols 9 and 10, respectively. Acylation of these gave compounds with the general formula 11 and 12, Scheme 2. All compounds were characterized by both 1 H and 13 C NMR and high-resolution mass spectrometry, which assured their structure assignments (see the Supporting Information).
The above compounds were tested in the CYP3A4 assay. The results are presented as inhibition activity relative to dillapiol activity = 1. The primary data set including mean IC 50 values and 95% CIs for esters, 17 prepared from dillapiol and 10 from sesamol, are provided in Tables 1 and 2 , respectively. Although the raw IC 50 values of 27 ester analogues showed a lower trend (i.e., higher inhibition) than that of dillapiol (9.2 μM), statistical analysis revealed that only 15 analogues possessed significantly greater CYP3A4 inhibition activity than dillapiol (df = 47, 96; F = 106.5; P < 0.05). These are highlighted with * in these tables. For the remaining compounds, Tables 3−5 , only their inhibition activity relative to dillapiol is presented. To ensure consistency, dillapiol was included as the standard in each set of measurements, typically 5 to 8 compounds. The IC 50 value for dillapiol was consistent in the 8.9−9.2 μM range.
■ RESULTS AND DISCUSSION
Much of the impetus of this research came from an earlier observation by our group that the tertiary alcohol 13 obtained by condensation of the allyl anion derived by the reaction of dillapiol with n-BuLi in THF at −78°C with benzophenone strongly inhibited CYP3A4. 16 The synthesis of 13 was repeated, and its CYP3A4 inhibition was found to be 5.8 times more potent than that of dillapiol. The hydrogenolysis product 14 and the alkene metathesis product 15 had similar potency, while the dillapiol dimer 16 was 13 times more potent than dillapiol 17 (Table 3 ). Both the alcohols 2 and 3 were less potent than dillapiol in inhibiting CYP3A4. The data in Table 1 show that for the esters derived from the primary alcohol 2, an increase in size of the R group, particularly if near the ester function itself, resulted in increased CYP3A4 inhibition. For example, the acetate 4a (R = CH 3 ) has essentially the same inhibitory effect as dillapiol. The change in R from CH 3 (4a) to nC 5 H 11 (4d) to cyclohexyl (4e) to Bu t (4a) resulted in increased inhibition by factors of 2.8, 3, 4, and 4.8, respectively. The benzoyl ester (4h) is 4.4 times more potent inhibitor than the methyl ester. Chlorine substituents on the aromatic ring further increase the potency of these compounds to statistically significant values of greater than 6 (4h, 4i, 4j). The greatest change was observed when a hydrogen in the benzyl group (4m) was replaced by a second aromatic ring to yield R = benzhydryl (4n, 5n). This increased inhibition by a factor of 5 makes 4n 23 times more potent than dillapiol. The benzhydryl ester, 5n, of the secondary alcohol 5 is twice as active as 4n (46 times dillapiol). On the basis of this result, several other benzhydryl esters were prepared. The esters of the secondary alcohol were more potent than those of the isomeric primary alcohol. The benzhydryl ester 12, derived from the secondary alcohol 10 (R = CH 2 Ph) (Scheme 2), gave an IC 50 value of 0.16 μM making it almost 60 times more potent than dillapiol. It is among the most potent CYP 3A4 inhibitors reported in this study (Scheme 3).
Comparison of the same esters derived from dillapiol and sesamol suggests that the removal of the 4-methoxy group in dillapiol does not have a significant effect on the inhibition of the CYP3A4 enzyme. For example, the benzoyl esters 4g and
Scheme 1. Preparation of Esters Starting with Dillapiol Scheme 2. Preparation of Sesamol Derivatives

ACS Omega
Article 9a inhibit this enzyme to essentially the same extent. The same conclusion can be drawn when one compares data for the benzhydryl esters 4n and 9f; each of these compounds is approximately 20 times as effective as dillapiol. The replacement of the 5-methoxy group in the sesamol derivatives by benzyloxy groups (Scheme 4) (9b and 9g) lowers the inhibitory activity of these compounds by a factor of 2−3. This is opposite to the results observed for the corresponding 6-allyl derivatives where the benzyl ether 8c was significantly more active than the methyl ether 8b.
The in vivo bioassays reported by Liu 13 showed that only the highly hindered benzhydryl esters had good synergistic activity as anticipated by their in vitro CYP3A4 inhibition. The less hindered esters such as the methyl ester 4a and the benzoyl ester 4g showed no insecticide synergism of pyrethrum against the Colorado potato beetle likely due to insect esterase activity, which would convert these compounds back to the inactive alcohols 2, 3, 9, and 10. The metabolically more stable ethers, for example, 8b showed the increased in vivo synergism relative to dillapiol expected on the basis of its increased inhibition of CYP3A4.
A series of benzylic ethers 8b−8o were prepared from sesamol via the allylated phenol 7 (Table 5) . A number of these compounds where R is C 6 H 13 and CH 2 Ph showed modest enhancements in potency in comparison to dillapiol with the hexyl ether showing 4.8-fold and the benzyl ether 6.8-fold increases, respectively. Most of the other analogues had similar CYP3A4 inhibitory activity with values ranging from 0.9 times the activity of dillapiol for the O-methoxy derivative 8g to 8 times for the O-methyl compound 8e. Several derivatives stood out, in particular, the O-chloro analogue 8f and the 1-naphthyl ether 8m, which inhibited CYP3A4 86 and 26 times more effectively than dillapiol. These compounds have inhibitory activity comparable to the most potent benzhydryl esters 5n and 11i and the sulfones 18 and 19. The benzyl ethers 8n and 8o, which have 2-methylpropenyl and 2-chloropropenyl side chain at C6, respectively, were 15 and 12.6 times more potent inhibitors than dillapiol, suggesting that a combination of a more hindered side chain at C6 coupled with appropriate ortho-substitution in the 5-benzyloxy moiety could lead to even more potent CYP3A4 inhibitors. Replacement of the benzoyl ester function in 4g by a benzyl ether yielding 17a and 17b resulted in a decrease of the in vitro potency (Table 4) .
A group of benzylic ethers 8 were selected by BASF for evaluation as insecticide synergists against economically important insects in combination with common insecticides and their potential to be registered by Environmental Protection agencies. The initial results are encouraging and will be reported when the evaluation is complete.
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■ CONCLUSIONS Qualitative analysis of the inhibition data for a variety of esters indicates that the larger acyl group attached to alcohols 4, 5, 11, and 12 gives higher in vitro inhibition of CYP3A4. Additionally, it appears that the same esters derived from the secondary alcohols, for example, 5n and 12, are approximately twice as potent as those obtained from the isomeric primary alcohols, for example, 4n and 11i. In the case of ethers 8b−8o, the replacement of the remaining 5-methoxy group by other larger substituents such as O-hexyl, O-benzyl, in particular, several ortho-substituted benzyl analogues, and O-1-naphthyl resulted in significant increases in the inhibitory property of these compounds relative to dillapiol.
The replacement of the diphenylacetic acid moiety in compounds such as 10i and 12 by a phenylsulfonyl group resulted in the most potent CYP3A4 inhibitors we have produced thus far with 18 and 19 (Scheme 5) having IC 50 values of 0.086 and 0.13 μM, respectively. Thus, 18 is 107 times and 19 is 70 times more potent than dillapiol as inhibitors of this CYP 3A4 enzyme. The sulfones, unlike the esters, are not subject to esterase metabolism in the insects and therefore more likely to be effective in field trials.
Additional structure modifications, potentially guided by a QSAR developed from the available data, 16, 17, 19 designed to enhance the potency of sesamol and dillapiol derivatives as CYP3A4 inhibitors, in particular, various ether and sulfone analogues, and the testing of these compounds in in vitro and the field will be reported in the future.
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